


**Certification of Mailing Under 37 CFR § 1.10**

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date December 5 2003, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number Express Mail No.: EV 338302940US, addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Winsome Dunn

DOCKET NO. 21545-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Frank Bergmann, et al.

EXAMINER: Unassigned

SERIAL NO.: Unassigned

ART UNIT: Unassigned

FILED: Even date herewith

FOR: MANNITOL AND GLUCITOL  
DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed concurrently with the Request for a Utility Application. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812. A duplicate copy of this communication is enclosed.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third

parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: December 5 2003

  
Charles M. Doyle (Reg. No. 39,175)

Correspondence Address  
Customer No. 22829  
ROCHE MOLECULAR SYSTEMS, INC.  
Patent Department  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: 510-814-2800  
Fax: 510-814-2973

FORM PTO-1449 Patent and Trademark Office		Atty. Docket No. 21545-US1		Applicant: Frank Bergmann, et al			
<b>FOREIGN PATENT DOCUMENTS</b>							
		WO 97/43451	11/20/97	PCT			
		WO 99/09044	2/25/99	PCT			
		WO 01/37291 A1	5/25/01	PCT			
		WO 02/12263 A1	2/14/02	PCT			
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Abramson, R., et al., 1993, "Nucleic Acid Amplification Technologies", <i>Current Opinion in Biotechnology</i> , 4:41-47					
		Andersen, M., et al., 1996, "The Synthesis of Modified D- and L- Anhydrohexitol Nucleosides", <i>Tetrahedron Letters</i> , 37(45):8147-8150					
		Barany, F., 1991, "Review: The Ligase Chain Reaction in a PCR World", <i>PCR Methods and Applications</i> , pp 5-16					
		Barany F., 1991, "Genetic Disease detection and DNA amplification using cloned thermostable ligase", <i>Proc. Natl. Acad. Sci. USA</i> , 88:189-193					
		Beaucage, S., et al., 1981, "Deoxynucleoside Phosphoramidites – a New Class of Key Intermediates for Deoxypolynucleotide Synthesis", <i>Tetrahedron Letters</i> , 22(20):1859-1862					
		Brown, E., et al., 1979, "Chemical Synthesis and Cloning of a Tyrosine tRNA Gene", <i>Methods in Enzymology</i> , 68:109-151					
		Garegg, P., et al., 1985, "Formation of Internucleotidic Bonds via Phosphonate Intermediates", <i>Chemical Scripta</i> , 25:280-282					
		Gregrich, H., et al., 1998, "New Photolabile Protecting groups in Nucleoside and Nucleotide Chemistry – Synthesis, Cleavage Mechanisms and Applications", <i>Nucleosides and Nucleotides</i> , 17(9-11):1987-1996					
		Gutelli, J., et al., 1990, "Isothermal, <i>in vitro</i> amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", <i>Proc. Natl. Acad. Sci. USA</i> , 87:1874-1878					
		Hossain, N., et al., 1998, "Oligonucleotides Composed with 2'-Deoxy-1',5'-anhydro-D-mannitol Nucleosides with a Purine Base Moiety", <i>J. Org. Chem</i> , 63:1574-1582					
		Narang, S., et al., 1979, "Improved Phosphotriester method for the Synthesis of Gene Fragments", <i>Methods in Enzymology</i> , 68:90-98					
		Jesús, M., et al., 1996, "Synthesis and Antiviral Activity of 2-Deoxy-1,5-Anhydro-D-Mannitol Nucleosides containing a pyrimidine base moiety", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 6(13):1457-1460					
		Pravdić, N., et al., 1973, "Catalytic Hydrogenation of some 2-Acetamidoaldose Derivatives*", <i>Croatica Chemica Acta</i> , 45:343:356					
		Su, S., et al., 1997, "Novel Non-Nucleosidic Phosphoramidites for Oligonucleotide Modification and Labeling", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 7(13):1639-1644					
		Uhlmann, E., et al., 1990, "Antisense Oligonucleotides: A new Therapeutic Principle", <i>Chemical Reviews</i> , 90(4):543-584					
		Van Aerschot, A., et al., 1993, Synthesis of nucleoside analogues with a 1,5-anhydrohexitol moiety", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 3(60):1013-1018					
		Verheggen, I., et al., 1993, "Synthesis and antiherpes Virus Activity of 1,5-anhydrohexitol nucleosides", <i>J Med. Chem.</i> , 36:2033-2040					
		Verheggen, I., et al, 1995, Synthesis, biological evaluation and structure analysis of a series of new 1,5-anhydrohexitol nucleosides", <i>J Med. Chem.</i> , 38:826:835					
		Verma, S., et al., 1998, "Modified Oligonucleotides: Synthesis and Strategy for Users", <i>Annu Rev. Biochem.</i> , 67:99-134					
		Whelen, A., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical Microbiology Laboratory <sup>1</sup> ", <i>Annu Rev. Biochem.</i> , 50:349-373					
		Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR)- Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation", <i>Genomics</i> , 4:560-569					
EXAMINER			DATE CONSIDERED				
<p>*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 21545-US1		Serial No. Unassigned		
<b>LIST OF INFORMATION CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant: Frank Bergmann, et al.				
				Filing Date: Even date		Group: Unassigned		
<b>U.S. PATENT DOCUMENTS</b>								
* EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		4,458,066	7/3/84	Caruthers, et al.	536	27	3/24/81	
		4,996,143	2/26/91	Heller, et al.	435	6	4/13/90	
		5,130,238	7/14/92	Malek, et al.	435	91	8/23/89	
		5,210,015	5/11/93	Gelfand, et al.	435	6	8/6/90	
		5,451,463	9/19/95	Nelson, et al.	428	402	6/3/93	
		5,478,972	12/26/95	Mizutani, et al.	435	6	8/25/94	
		5,487,972	1/30/96	Gelfand, et al.	435	6	1/5/93	
		5,565,322	10/15/96	Heller, M.	435	6	5/5/94	
		5,804,375	9/8/98	Gelfand, et al.	435	6	4/25/95	
		5,849,489	12/15/98	Heller, M.	435	6	8/23/96	
		6,103,476	8/15/00	Tyagi, et al.	435	6	3/15/99	
		6,130,323	10/10/00	Su, et al.	536	23.1	10/26/98	
		6,162,603	12/19/00	Heller, M.	435	6	7/28/98	
		6,174,670	1/16/01	Wittwer, et al.	435	6	6/4/97	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
		DE 3943522 A1	2/7/91	Germany				X
		EP 0 135 587 B2	12/18/02	EP				
		EP 0 313 219 B1	5/8/96	EP				
		EP 0 439 182 B1	4/24/96	EP				
		WO 90/01069	2/8/90	PCT				
		WO 92/08808	5/29/92	PCT				
		WO 93/25565	12/23/93	PCT				
		WO 96/05213	2/22/96	PCT				
		WO 96/41811	12/27/96	PCT				
EXAMINER				DATE CONSIDERED				
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								